CN106659717B - 用于治疗淋病奈瑟球菌感染的三环含氮化合物 - Google Patents

用于治疗淋病奈瑟球菌感染的三环含氮化合物 Download PDF

Info

Publication number
CN106659717B
CN106659717B CN201580045166.8A CN201580045166A CN106659717B CN 106659717 B CN106659717 B CN 106659717B CN 201580045166 A CN201580045166 A CN 201580045166A CN 106659717 B CN106659717 B CN 106659717B
Authority
CN
China
Prior art keywords
dihydro
mmol
methyl
piperidinyl
give
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580045166.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN106659717A (zh
Inventor
K.L.威多森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Priority to CN201910738641.XA priority Critical patent/CN110403939A/zh
Publication of CN106659717A publication Critical patent/CN106659717A/zh
Application granted granted Critical
Publication of CN106659717B publication Critical patent/CN106659717B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201580045166.8A 2014-08-22 2015-08-20 用于治疗淋病奈瑟球菌感染的三环含氮化合物 Active CN106659717B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910738641.XA CN110403939A (zh) 2014-08-22 2015-08-20 用于治疗淋病奈瑟球菌感染的三环含氮化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040488P 2014-08-22 2014-08-22
US62/040,488 2014-08-22
PCT/IB2015/056325 WO2016027249A1 (en) 2014-08-22 2015-08-20 Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910738641.XA Division CN110403939A (zh) 2014-08-22 2015-08-20 用于治疗淋病奈瑟球菌感染的三环含氮化合物

Publications (2)

Publication Number Publication Date
CN106659717A CN106659717A (zh) 2017-05-10
CN106659717B true CN106659717B (zh) 2019-09-06

Family

ID=54072911

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580045166.8A Active CN106659717B (zh) 2014-08-22 2015-08-20 用于治疗淋病奈瑟球菌感染的三环含氮化合物
CN201910738641.XA Pending CN110403939A (zh) 2014-08-22 2015-08-20 用于治疗淋病奈瑟球菌感染的三环含氮化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910738641.XA Pending CN110403939A (zh) 2014-08-22 2015-08-20 用于治疗淋病奈瑟球菌感染的三环含氮化合物

Country Status (22)

Country Link
US (2) US10702521B2 (https=)
EP (2) EP3639824A1 (https=)
JP (2) JP6546654B2 (https=)
KR (1) KR20170043603A (https=)
CN (2) CN106659717B (https=)
AR (1) AR101674A1 (https=)
AU (1) AU2015304847B2 (https=)
BR (1) BR112017003705B1 (https=)
CA (1) CA2958800C (https=)
CL (1) CL2017000391A1 (https=)
CO (1) CO2017001658A2 (https=)
CR (1) CR20170069A (https=)
DO (1) DOP2017000049A (https=)
EA (1) EA031589B1 (https=)
ES (1) ES2759303T3 (https=)
IL (1) IL250251A0 (https=)
MX (1) MX2017002321A (https=)
PE (1) PE20170501A1 (https=)
PH (1) PH12017500315A1 (https=)
SG (1) SG11201700566SA (https=)
TW (1) TW201618779A (https=)
WO (1) WO2016027249A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702521B2 (en) * 2014-08-22 2020-07-07 Glaxosmithkline Intellectual Property Development Limited Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones
ME03738B (me) 2016-06-08 2021-01-20 Acraf Novi antibakterijski spojevi
EP3555050A1 (en) 2016-12-16 2019-10-23 Basf Se Pesticidal compounds
EP3946342A1 (en) * 2019-04-03 2022-02-09 GlaxoSmithKline Intellectual Property Development Limited Gepotidacin for use in the treatment of bacterial urinary tract infections
US20220184071A1 (en) * 2019-04-03 2022-06-16 Glaxosmithkline Intellectual Property Development Limited Gepotidacin for use in the treatment of bacterial urinary tract infections
GB201909191D0 (en) * 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
US20220257615A1 (en) * 2019-07-05 2022-08-18 Glaxosmithkline Intellectual Property Development Limied Combination for the treatment of infections caused by mycoplasma genitalium
CN115151540A (zh) 2019-12-02 2022-10-04 风暴治疗有限公司 作为mettl3抑制剂的多杂环化合物
EP4125905B1 (en) 2020-04-02 2024-12-25 GlaxoSmithKline Intellectual Property Development Limited Regimen for treating a neisseria gonorrhoeae infection with gepotidacin
EP4142731A1 (en) * 2020-04-28 2023-03-08 Noorik Biopharmaceuticals AG Treatment of pulmonary complications of coronavirus infections
US12528809B2 (en) 2020-04-29 2026-01-20 Glaxosmithkline Intellectual Property Development Limited Crystalline forms of gepotidacin
EP4288035A1 (en) 2021-02-05 2023-12-13 GlaxoSmithKline Intellectual Property Development Limited Oral solid dose formulations
EP4316463A1 (en) 2022-08-02 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Novel formulation
JP2025532252A (ja) 2022-09-26 2025-09-29 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 処置方法
CN121537412B (zh) * 2026-01-16 2026-04-03 南京道尔医药研究院有限公司 一种吉泊达星甲磺酸盐的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128942A1 (en) * 2007-04-20 2008-10-30 Glaxo Group Limited Tricyclic nitrogen containing compounds as antibacterial agents
WO2010043714A1 (en) * 2008-10-17 2010-04-22 Glaxo Group Limited Tricyclic nitrogen compounds used as antibacterials

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA931343B (en) 1992-03-06 1993-09-24 Akzo Nv 1,4-dioxino(2,3-b)pyridine derivatives.
EP0624376B1 (en) * 1993-05-13 2000-03-15 American Cyanamid Company Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci
GB0207450D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
EP1306038B1 (en) 2000-07-21 2005-12-21 Ljudmila Petrovna Maljuk Plate for a stand-up meal
EP1305308B1 (en) 2000-07-26 2006-12-20 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
BR0114321A (pt) 2000-09-29 2003-07-01 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar um composto
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
EP1345903A1 (en) 2000-12-21 2003-09-24 Ciba SC Holding AG Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
EP1470131A2 (en) 2002-01-29 2004-10-27 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
US7312212B2 (en) 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
EP1551829B1 (de) 2002-10-10 2010-04-07 Morphochem Aktiengesellschaft Für Kombinatorische Chemie Neue verbindungen mit antibakterieller aktivität
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
US7232832B2 (en) 2002-11-05 2007-06-19 Smithkline Beecham Corporation Antibacterial agents
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
WO2004104000A1 (ja) 2003-05-23 2004-12-02 Japan Tobacco Inc. トリサイクリック縮合環化合物およびその医薬用途
FR2858619B1 (fr) 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
WO2006002047A2 (en) 2004-06-15 2006-01-05 Glaxo Group Limited Antibacterial agents
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
JP2008505920A (ja) 2004-07-08 2008-02-28 グラクソ　グループ　リミテッド 抗菌剤
US20080194547A1 (en) 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
JP2008506695A (ja) 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
US20070270417A1 (en) 2004-07-22 2007-11-22 Glaxo Group Limited Antibacterial Agents
WO2006017468A2 (en) 2004-08-02 2006-02-16 Glaxo Group Limited Antibacterial agents
JP2008509222A (ja) 2004-08-09 2008-03-27 グラクソ グループ リミテッド 抗菌剤
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
JP4887297B2 (ja) 2004-09-24 2012-02-29 アクテリオン ファーマシューティカルズ リミテッド 新規二環式抗生物質
DE602005021133D1 (de) 2004-10-05 2010-06-17 Actelion Pharmaceuticals Ltd Neue piperidin-antibiotika
JP5314244B2 (ja) 2004-10-27 2013-10-16 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
US7511035B2 (en) 2005-01-25 2009-03-31 Glaxo Group Limited Antibacterial agents
JP2008528586A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
JP2008528598A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
WO2006081182A2 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
EP1845995A4 (en) 2005-01-25 2010-03-03 Glaxo Group Ltd ANTIBACTERIAL AGENTS
WO2006099884A1 (en) 2005-03-24 2006-09-28 Actelion Percurex Ag Beta-aminoalcohol antibiotics
JP5023054B2 (ja) 2005-03-31 2012-09-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としての二環式ピラゾール化合物
TW200716132A (en) 2005-05-03 2007-05-01 Smithkline Beecham Corp Novel chemical compounds
MX2007014507A (es) 2005-05-24 2008-02-07 Astrazeneca Ab Aminopiperidin quinolinas y sus analogos azaisostericos con actividad antibacteriana.
ATE441645T1 (de) 2005-05-25 2009-09-15 Actelion Pharmaceuticals Ltd Neue antibiotische derivate
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
EP1900732A4 (en) 2005-06-24 2009-11-18 Toyama Chemical Co Ltd NEW NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF
WO2007016610A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited Antibacterial agents
ES2340531T3 (es) 2005-10-21 2010-06-04 Glaxo Group Limited Compuestos triciclos peri-condensados utiles como agentes antibacterianos.
AU2006322067A1 (en) 2005-12-06 2007-06-14 Merck Sharp & Dohme Corp. Morpholine carboxamide prokineticin receptor antagonists
ATE465163T1 (de) 2005-12-22 2010-05-15 Glaxo Group Ltd Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
EP2001887B1 (en) 2006-04-06 2010-09-15 Glaxo Group Limited Pyrrolo-quinoxalinone derivatives as antibacterials
WO2007118130A2 (en) 2006-04-06 2007-10-18 Glaxo Group Limited Antibacterial agents
GB0608263D0 (en) 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
JP2009539807A (ja) 2006-06-09 2009-11-19 グラクソ グループ リミテッド 抗菌薬としての置換１−メチル−１ｈ−キノリン−２−オンおよび１−メチル−１ｈ−１，５−ナフチリジン−２−オン
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
CA2725726A1 (en) * 2008-05-23 2009-11-26 Glaxo Group Limited Tricyclic nitrogen containing compounds and their use as antibacterials
US10702521B2 (en) * 2014-08-22 2020-07-07 Glaxosmithkline Intellectual Property Development Limited Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128942A1 (en) * 2007-04-20 2008-10-30 Glaxo Group Limited Tricyclic nitrogen containing compounds as antibacterial agents
WO2010043714A1 (en) * 2008-10-17 2010-04-22 Glaxo Group Limited Tricyclic nitrogen compounds used as antibacterials

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Determination of Disk Diffusion and MIC Quality Control Guidelines for GSK2140944,a Novel Bacterial Type II Topoisomerase Inhibitor Antimicrobial Agent;J.E.ROSS等;《JOURNAL OF CLINICAL MICROBIOLOGY》;20140701;第52卷(第7期);2629-2632 *

Also Published As

Publication number Publication date
KR20170043603A (ko) 2017-04-21
PE20170501A1 (es) 2017-04-27
JP6546654B2 (ja) 2019-07-17
CA2958800A1 (en) 2016-02-25
US20200330462A1 (en) 2020-10-22
EP3182973B1 (en) 2019-09-18
DOP2017000049A (es) 2017-03-15
PH12017500315A1 (en) 2017-07-10
CN110403939A (zh) 2019-11-05
BR112017003705B1 (pt) 2022-07-12
US20170304301A1 (en) 2017-10-26
JP2017524029A (ja) 2017-08-24
AR101674A1 (es) 2017-01-04
CN106659717A (zh) 2017-05-10
AU2015304847A1 (en) 2017-02-23
CA2958800C (en) 2020-10-27
CL2017000391A1 (es) 2017-08-18
EP3639824A1 (en) 2020-04-22
EA031589B1 (ru) 2019-01-31
BR112017003705A2 (pt) 2017-12-05
US10702521B2 (en) 2020-07-07
MX2017002321A (es) 2017-08-02
SG11201700566SA (en) 2017-03-30
WO2016027249A1 (en) 2016-02-25
EA201790442A1 (ru) 2017-08-31
IL250251A0 (en) 2017-03-30
TW201618779A (zh) 2016-06-01
ES2759303T3 (es) 2020-05-08
JP2019189629A (ja) 2019-10-31
EP3182973A1 (en) 2017-06-28
CO2017001658A2 (es) 2017-07-19
US11229646B2 (en) 2022-01-25
AU2015304847B2 (en) 2018-10-25
CR20170069A (es) 2017-04-28

Similar Documents

Publication Publication Date Title
CN106659717B (zh) 用于治疗淋病奈瑟球菌感染的三环含氮化合物
CN101687887B (zh) 用作抗菌剂的含氮三环化合物
EP2041145B1 (en) Azatricyclic compounds and their use
US7732460B2 (en) Heterocyclic compounds, their preparation and their use as antibacterials
US20100087424A1 (en) Tricyclic nitrogen containing heterocycles as antibacterial agents
US20100184751A1 (en) Heterocyclic compounds for the treatment of tuberculosis
US20110275661A1 (en) Tricyclic nitrogen compounds used as antibacterials
HK1138000B (en) Tricyclic nitrogen containing compounds as antibacterial agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Steve Niki

Patentee after: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT Ltd.

Country or region after: United Kingdom

Address before: British Meader Sykes

Patentee before: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT Ltd.

Country or region before: United Kingdom